Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

• Author(s): Rondy, Marc ; Gherasim, Alin ; Casado, Itziar ; Launay, Odile ; Rizzo, Caterina ; Pitigoi, Daniela ; Mickiene, Aukse ; Marbus, Sierk D ; Machado, Ausenda ; Syrjänen, Ritva K ; Pem-Novose, Iva ; Horváth, Judith Krisztina ; Larrauri, Amparo ; Castilla, Jesús ; Vanhems, Philippe ; Alfonsi, Valeria ; Ivanciuc, Alina E ; Kuliese, Monika ; van Gageldonk-Lafeber, Rianne ; Gomez, Veronica ; Ikonen, Niina ; Lovric, Zvjezdana ; Ferenczi, Annamária ; Moren, Alain ; I-MOVE+ hospital working group
• Date: 2017
• Persistent ID: http://hdl.handle.net/10400.18/5071
• Origin: Repositório Científico do Instituto Nacional de Saúde
• Subject(s): A(H3N2); Influenza; Cases Control;; Elderly; Hospitalisation; Vaccine Effectiveness; Vacina Antigripal; Cuidados de Saúde; Efetividade da Vacina Antigripal
• Document Type: Journal article
• Language: English
• Contributor(s): Repositório Científico do Instituto Nacional de Saúde

Description

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.